Boothbay Fund Management LLC Has $3.81 Million Stock Holdings in CG Oncology, Inc. $CGON

Boothbay Fund Management LLC grew its holdings in CG Oncology, Inc. (NASDAQ:CGON) by 67.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 94,479 shares of the company’s stock after purchasing an additional 38,224 shares during the period. Boothbay Fund Management LLC owned approximately 0.12% of CG Oncology worth $3,806,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of CG Oncology by 190.3% during the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock worth $222,055,000 after buying an additional 3,613,885 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of CG Oncology by 15.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after acquiring an additional 281,637 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of CG Oncology by 409.9% during the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after acquiring an additional 1,396,170 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of CG Oncology by 12.7% during the 2nd quarter. Franklin Resources Inc. now owns 1,486,839 shares of the company’s stock valued at $38,658,000 after acquiring an additional 167,905 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

Analyst Ratings Changes

CGON has been the subject of a number of recent research reports. Wedbush assumed coverage on CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 target price for the company. HC Wainwright boosted their price target on CG Oncology from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Royal Bank Of Canada upped their price objective on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Piper Sandler raised their price objective on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $69.00.

CG Oncology Trading Up 2.5%

Shares of CGON stock opened at $65.90 on Tuesday. CG Oncology, Inc. has a 1-year low of $14.80 and a 1-year high of $66.81. The stock has a market cap of $5.56 billion, a price-to-earnings ratio of -31.84 and a beta of 1.17. The stock has a 50-day moving average of $55.18 and a 200-day moving average of $45.11.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million during the quarter. Sell-side analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Activity

In other news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.